Abstract: TH-PO901
Long-Term Effect of COVID-19 Infection on Kidney Function Among COVID-19 Patients Followed in a Post-COVID-19 Recovery Clinic in British Columbia, Canada
Session Information
- COVID-19: Long COVID
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Thompson, Jordyn R., The University of British Columbia, Vancouver, British Columbia, Canada
- Atiquzzaman, Mohammad, BC Provincial Renal Agency, Vancouver, British Columbia, Canada
- Shao, Selena, BC Provincial Renal Agency, Vancouver, British Columbia, Canada
- Djurdjev, Ognjenka, BC Provincial Renal Agency, Vancouver, British Columbia, Canada
- Levin, Adeera, The University of British Columbia, Vancouver, British Columbia, Canada
- Birks, Peter C., The University of British Columbia, Vancouver, British Columbia, Canada
Background
Recent research suggests that COVID-19 is associated with acute kidney dysfunction. Effect of COVID-19 infection on downstream kidney function is unknown. We investigated this using the BC Interdisciplinary COVID-19 Care Network data.
Methods
This retrospective cohort study analyzed a 2,212 COVID-19 patient cohort, aged ≥18 years, referred to the Post COVID Recovery Clinic (PCRC) in BC, Canada between July 9, 2020 & April 21, 2022. COVID-19 diagnosis date was the index date. Patients with history of kidney transplantation or dialysis before index date were excluded. Patients who deceased within 3 months of cohort entry were excluded. eGFR values were retrieved from the Provincial Laboratory Information System. We examined change in eGFR at 3-, 6-, 12-months after COVID-19 infection among the same study individuals using linear mixed model. Subgroup analysis included comparison between hospitalized vs. non-hospitalized, & diabetics vs. non-diabetics.
Results
Analytic cohort included 457 patients (median age 59 years, 50% male) for whom eGFR was recorded at 3-, 6-, 12-months from index date. Prevalence of reduced eGFR (≤59ml/min/1.73m2) was 16%, 16%, 17% at 3-, 6- and 12- months post-index date, respectively. Median (IQR) eGFR at baseline was 90 (73, 102) that was reduced to 85 (70, 101) at 6-months & remained stable or <previous value at 12 months post-index date, 86 (69, 101). Results from linear mixed model indicated a 0.23 ml/min decrease in eGFR in each month after COVID-19 infection (intercept 85.51, slope -0.23, p-value=0.0003). In subgroup analyses, similar trends of decreasing eGFR over time were observed among diabetic (n=188, intercept 83.08, slope -0.42, p-value=0.0001) & non-diabetic patients (n=269, intercept 87.33, slope -0.12, p-value=0.13). Interestingly, eGFR appeared to improve over time in non-hospitalized patients (n=133, intercept 88.34, slope 0.24, p-value=0.03) compared to a decreasing trend among hospitalized patients (n=324, intercept 83.94, slope -0.41, p-value=<0.001).
Conclusion
One in 6 COVID-19 patients who were referred to PCRC had reduced eGFR. COVID-19 was associated with a statistically significant decrease in eGFR, particularly in diabetic & hospitalized patients that warrants ongoing monitoring following COVID-19 infection.